Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our potential product, Onrigin™ (laromustine), formerly Cloretazine® (VNP40101M) is being evaluated for the treatment of acute myelogenous leukemia (AML) in a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition, four clinical trials of Onrigin™ (laromustine), formerly Cloretazine® (VNP40101M) are underway in: (i) AML and myelodysplastic syndrome (MDS) in combination with cytarabine; (ii) AML and MDS in combination with standard remission-induction therapy; (iii) brain tumors in combination with temozolomide; and (iv) advanced hematologic malignancies in combination with hematopoietic cell transplantation. Our second potential product, Triapine®, is being evaluated in trials sponsored by the National Cancer Institute.
Vion Presents Additional Survival Data on Onrigin™ (Laromustine) Injection at ASH Annual Meeting
Vion Poster Slides – 50th Annual Meeting of the American Society of Hematology (ASH)
Vion Poster – 50th Annual Meeting of the American Society of Hematology (ASH)
Vion to Present Survival Data on Laromustine at ASH Annual Meeting
Vion Adds Tanya Lewis to Senior Management Team
Vion Updates Conference Call Information
Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday November 6 at 8:30 a.m.
Vion Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine® in Combination with Induction Therapy in Poor Prognosis AML Patients
Vion Enters into Agreement with HOVON to Conduct a Phase III Clinical Trial of Cloretazine® in combination with Frontline AML and MDS Therapy
Vion Conference Call